

18TH Congress of the European Society for Organ Transplantation



24 - 27 September 2017
Barcelona, Spain



Transplantation BigBangBarcelona

Advanced programme



Dear Colleagues, Dear Friends,

The 18th Congress of ESOT will take place in Barcelona, one of the most cosmopolitan and attractive cities of the South Europe and the Mediterranean area. The ESOT 2017 Congress will include most of the hot topics in modern transplant medicine like personalized medicine, big data in transplantation and challenges in innovation. Also relevant clinical and immunological topics on solid organ transplantation will be discussed. Finally, new technologies, and the race between repair or create new organs will be updated. All this exciting programme will be developed by the top experts coming worldwide.

Barcelona is the perfect host city; it interweaves tradition and avant-garde into a multi-layered identity, from the history-laden Gothic quarter to the 22@district, reaching out the future: from the masterpieces of local modernism to the statements of global architects; from Cuatre Gats, that guards

culinary tradition, to chef Ferran Adrià's cutting edge innovation lab; from the unique Catalan heritage to the diversity brought by multi-ethnicity; from the buzz of its markets to the vitality of its research centres and universities. Energy and passion are palpable anywhere: among those enamoured and inspired by the city are designers, artists, architects, entrepreneurs who have chosen it as a stage for their intricate creations or flocks of tourists marvelled by the city's visual charms and romantic flair. Barcelona is a modern and sophisticated city with a very rich cultural life and has a broad offer of leisure opportunities to satisfy and delight delegates.

Both the Spanish and Catalan Transplantation Societies, together with the local scientific community, welcome you on board and look forward to seeing you in Barcelona!

Valentín Cuervas-Mons and Antonio Román
CONGRESS CHAIRS

Dear Colleagues, Dear Friends,

We would like to invite you to a new level of medical meetings in transplantation at the **BigBangBarcelona** conference. Transplantation has emerged from the decades of an early experimental procedure to an established first line therapy for organ failure. While mechanistic devices or fully artificial organs may be available in many decades from now, the fate of the patients suffering from organ failure today and in the next years, will depend on the progress we will achieve with transplantation.

The discrepancy between the high demand and the shortage in organs available remains a challenge. Amongst the many obstacles highlighted at the congress, progress in transplantation with organs from living donors but also advancements in normothermic perfusion and other seminal technologies will be addressed. Novel drugs, protocols for immunomodulation and tolerance but also surrogate endpoints for clinical trials in order to enhance the drug development remain critically important topics in the field. The **BigBangBarcelona** congress might help to refine our knowledge of basic science and clinical concepts to improve transplantation in a holistic approach.

At ESOT we have put a focus on the quality of the science but also the formats in which the content is delivered and the opportunity to network with your colleagues. The fully digital conference, the ALLIESOTApp, the Hybrid Meeting Concept are only few examples of how ESOT has modernized medical conferencing. In 2017, the technological enhancement of your conference experience will be nothing short of groundbreaking.

Barcelona was the venue of the ESOT congress in 1989 when ESOT was a young society that crystalized an emergent European transplant community with the eclosion of solid organ transplant programs after the introduction of cyclosporine. Today, Barcelona is a paradigm of a vibrant Mediterranean city, the home of Gaudí, the home of Las Ramblas and Lionel Messi's right and left legs. Barcelona is home to modern art, home to spotless beaches, home to eternal nightlife, home to eminent romance and modern charme. Come on and join us at **BigBangBarcelona**.

Josep Maria Grinyó and Stefan Schneeberger
SCIENTIFIC PROGRAMME COMMITTEE CHAIRS

Top ten reasons to attend



- 1 Enjoy a stimulating, rejuvenated format with a focus on interaction and information exchange **and** the latest developments in the field of transplantation.
- 2 Be inspired, educated, connected and entertained.
- 3 Discuss with experts and innovative thinkers from all fields.
- 4 Understand the latest trends in biomarkers, biologicals and immunosuppression and how this may change patient care.
- 5 Learn about the latest discoveries in the science of transplantation and aging.
- 6 Experience translational research and recent developments at the interjunction between basic science and clinical care.
- 7 Attend sessions addressing the greatest surgical or immunological challenges.
- 8 Discuss present and upcoming challenges in transplantation: where business, legislation and medicine/science meet.
- 9 Present your work and be selected as a case/topic for focused discussions – guided and instructed by key opinion leaders in the field.
- 10 Get engaged in this interactive meeting and take an active role in shaping the future of transplantation research and medicine.

Index

Welcome to BigBangBarcelona	2
Top ten reasons to attend	3
Scientific programme overview	4
Congress Committees and ESOT Council	6

SCIENTIFIC PROGRAMME

Specialty symposia and special sessions	8
Sunday 24 September	19
Monday 25 September	20
Tuesday 26 September	25
Wednesday 27 September	31
Transplant Education Campfire	34
How to submit an abstract	35
What is an Elevator Pitch?	36
Registration fees	37
ESOT awards 2017	38
ESOT partners and congress supporters	40
Corporate symposia	42
General information	43

SUNDAY 24 SEPTEMBER**MONDAY 25 SEPTEMBER**

TUESDAY 26 SEPTEMBER

7.30	EDUCATIONAL TRACK			
8.00	3 Above and below the diaphragm	4 Pathophysiology and endpoints on tolerance	Full Orals	Brief Orals
9.00				
9.10	STATE OF THE ART			
	4 New concepts in transplant infectious diseases: microbiota and beyond	5 Cell therapy in clinical trials	6 One for all or all for one: getting away from protocolized medicine	
10.40	Coffee break			
11.10	Big Bang 3 Innovation in immunomodulation: the modern Prometheus	Asia Leading The Way	Elevator Pitch	Full Orals
12.40				
13.00	Corporate Parallel Lunch Symposia	Surrogate Endpoints International Workshop	Brief Orals	
14.05	Plenary 3 Innovation under pressure: transplant patient care in 2020			
15.35	Coffee break			
16.00	Big Bang 4 Ageing and immortality	The Devil's Advocate Clinical	Brief Orals	
17.05	ESOT General Assembly	Corporate Parallel Symposia	Full Orals	
18.40	Elevator Pitch		Brief Orals	
19.35				
20.20	Rising Stars Networking Cocktail			

WEDNESDAY 27 SEPTEMBER

7.30	EDUCATIONAL TRACK			
8.00	5 Infection diseases	6 Allograft phenotype and clinical implications	Full Orals	Brief Orals
9.00				
9.10	STATE OF THE ART			
10.40	7 Donor management	8 Pushing the boundaries in living donation	9 Cellular interactions in rejection	
	Coffee break			
11.10	Plenary 4 and Presidential Session Leadership in Transplantation			
13.00				

Who should attend?

The target audience for this conference includes all fields in healthcare and research with an affiliation in transplantation. This includes but is not limited to:

- Transplant surgeons.
- Physicians of all fields with an involvement in transplantation.
- Psychologists, coordinators, nurses.
- General surgeons and clinicians with an interest in transplantation.
- Transplant sciences.
- Nutrition and rehabilitation specialists and coordinators.
- Transplant pharmacists.

Further, healthcare professionals with an involvement in treatment of organ failure, cell therapy, tissue and regenerative medicine are warmly welcome to our conference.



ESOT 2017 Congress Committee

CONGRESS CHAIRS

Valentín Cuervas-Mons, Madrid, Spain

Antonio Román, Barcelona, Spain

EXECUTIVE ORGANISING COMMITTEE

Josep Maria Grinyó, Barcelona, Spain

Stefan Schneeberger, Innsbruck, Austria

Maarten Naesens, Leuven, Belgium

Gabriel Oniscu, Edinburgh, United Kingdom

Olivier Thaunat, Lyon, France

Annalisa Ponchia, ESOT CEO



ESOT 2017 Scientific Program Committee

CHAIRS

Josep Maria Grinyó, Barcelona, Spain

Stefan Schneeberger, Innsbruck, Austria

MEMBERS

Marina Berenguer, Valencia, Spain

Oriol Bestard, Barcelona, Spain

Georg Böhmig, Vienna, Austria

Pietro Cippà, Zurich, Switzerland

Frans Claas, Leiden, The Netherlands

Valentín Cuervas-Mons, Madrid, Spain

Eelco de Koning, Leiden, The Netherlands

Marc Dahlke, Regensburg, Germany

Frank Dor, London, United Kingdom

Alexandre Loupy, Paris, France

Lorna Marson, Edinburgh, United Kingdom

Nicolas Müller, Zurich, Switzerland

Maarten Naesens, Leuven, Belgium

Arne Neyrinck, Leuven, Belgium

Gabriel Oniscu, Edinburgh, United Kingdom

Jacques Pirenne, Leuven, Belgium

Antonio Román, Barcelona, Spain

Hendrik Tevaearai, Bern, Switzerland

Olivier Thaunat, Lyon, France



ESOT 2017 Local Committee

CHAIR

Josep Maria Grinyó, Nephrology, Barcelona

MEMBERS

Gonzalo Crespo, Hepatology, Barcelona

María G. Crespo Leiro, Cardiology, La Coruña

José M^a Cruzado, Nephrology, Barcelona

Valentín Cuervas-Mons, Hepatology, Madrid
(President of the Spanish Transplantation Society)

Alex Gutiérrez-Dalmau, Nephrology, Zaragoza

Beatriz Domínguez-Gil, Nephrology, Madrid

Domingo Hernández Marrero, Nephrology,
Málaga

Laura Lladó, Hepatology, Surgery, Barcelona

Rafael López Andújar, Nephrology, Valencia

Marcos López-Hoyos, Immunology, Santander

Nuria Masnou, Organ Procurement, Intensive
Care, Girona

Sonia Mirabet, Cardiology, Barcelona

Francisco Moreso, Nephrology, Barcelona

Eduard Palou, Immunology, Barcelona

Antonio Román, Pulmonology, Barcelona
(President of the Catalan Transplantation Society)

Daniel Serón, Nephrology, Barcelona



ESOT 2017 Sponsorship Advisory Committee

MEMBERS

John Forsythe, Edinburgh, United Kingdom
Thierry Berney, Geneva, Switzerland
Stefan Schneeberger, Innsbruck, Austria
Vassilios Papalois, London, United Kingdom
Annalisa Ponchia, ESOT CEO



ESOT 2016 -2017 Council

PRESIDENT

Thierry Berney, Geneva, Switzerland

PRESIDENT ELECT

Stefan Schneeberger, Innsbruck, Austria

SECRETARY

Vassilios Papalois, London, United Kingdom

COUNCILLORS

Diego Cantarovich, Nantes, France
Franco Citterio, Rome, Italy
Marc Dahlke, Regensburg, Germany
Luuk Hilbrands, Nijmegen, The Netherlands
Maarten Naesens, Leuven, Belgium
Björn Nashan, Hamburg, Germany
Birgit Sawitzki, Berlin, Germany
Gabriel Oniscu, Edinburgh, United Kingdom
Olivier Thaumat, Lyon, France

PAST PRESIDENT

John Forsythe, Edinburgh, United Kingdom

TREASURER

Luciano Potena, Bologna, Italy

MEMBERS

Gerald Brandacher, Baltimore, United States
VCA Chair

Julien Charpentier, Paris, France
EDTCO Chair

Frank Dor, London, United Kingdom
EC Chair

Christophe Duvoux, Paris, France
ELITA Chair

Henri Leuvenink, Groningen, The Netherlands
BSC Chair

Emma Massey, Rotterdam, The Netherlands
ELPAT Chair

Arne Neyrinck, Leuven, Belgium
ECTTA Chair

Rainer Oberbauer, Vienna, Austria
EKITA Chair

Liset Pengel, London, United Kingdom
CET

Johann Pratschke, Berlin, Germany
EPITA Chair

Francesca Tinti, Rome, Italy
YPT Chair

Marjo Van Helden, Nijmegen, The Netherlands
ETAHP Chair

SPECIALTY UPDATE SYMPOSIUM ELITA



09.00 – 12.50

Bile ducts in liver transplantation - do we make progress?

09.00 – 10.40

Session 1

CHAIRS: Luca Belli, Milan, Italy

Wojciech Polak, Rotterdam, The Netherlands

Introduction

Christophe Duvoux, Paris, France and Gabriela Berlakovich, Vienna, Austria

09.15

Classification, epidemiology and pathophysiology of biliary complications after liver transplantation

Silvio Nadalin, Tübingen, Germany

09.35

How to treat the biliary tract during liver procurement and during transplantation?

Nicolas Meurisse, Liège, Belgium

09.55

Diagnostic work-up for biliary complications after liver transplantation

Gabriela Berlakovich, Vienna, Austria

10.40 – 11.00

Break

11.00 – 12.50

Session 2

CHAIRS: Giacomo Germani, Padova, Italy

Krzysztof Zieniewicz, Warsaw, Poland

11.10

Non-anastomotic strictures in DCD liver transplantation – how to prevent them?

Robert Porte, Groningen, The Netherlands

11.30

How far can we go with conservative management of biliary complications after liver transplantation?

Herold Metselaar, Rotterdam, The Netherlands

12.00

Good functioning graft with severe biliary complications - when is the right time for re-transplantation?

Darius Mirza, Birmingham, United Kingdom

12.30

How the pathologist can help clinician in decision making in case of biliary complications?

Desley Neil, Birmingham, United Kingdom

OBJECTIVES | To provide the liver transplant professionals with up to date information on donor selection, anatomical and surgical technical pitfalls and management of recipients after small for size syndrome in split and living donor liver transplants.

TARGET AUDIENCE | Liver transplant surgeons and hepatologists, HPB surgeons and general hepatologists, HPB oncologists, specialist nurses in liver transplantation, HPB, hepatology and oncology.



The European Liver and Intestine Transplantation Association is a multi-disciplinary Society of health professionals in liver and intestine transplantation which is the official professional society delegated by ESOT for liver and intestine transplantation in Europe.

GOALS | To provide a range of educational activities, stimulate discussion and influence European legislation in liver and intestine transplantation. To stimulate clinical research and publications from analysis of the registry, in partnership with the European Liver Transplant Registry.

AIMS | Our aim is to set guidelines and standards and to provide education and support in liver and intestine transplantation within the European Countries.

SPECIALTY UPDATE SYMPOSIUM EPITA

- 09.00 – 12.40 **New challenges: fair allocation (recipient) and donation (donor)**
- 09.00 – 10.40 **Session 1. New challenges for a fair allocation (recipient)**
CHAIRS: *Helmut Arbogast, Munich, Germany*
Steve White, Newcastle, United Kingdom
- 09.00 **Challenges in different countries. Eurotransplant is in there with the other countries**
Eelco de Koning, Leiden, The Netherlands
- 09.10 **Experiences with a common waiting list for islets Tx in the United Kingdom**
James Shaw, Newcastle, United Kingdom
- 09.25 **New allocation system: the Swiss solution**
Roger Lehmann, Zurich, Switzerland
- 09.35 **What about France?**
Marie-Alice Macher, France
- 09.50 **Pancreas allocation in North Italy Transplant program (NITp)**
Massimo Cardillo, Milan, Italy
- 10.15 **The first pancreas transplants were performed 50 years ago. One of the surgeons recalls how it happened and some consequences**
Frederick Merkel, Chicago, United States
- 10.40 – 11.10 **Break**
- 11.10 – 12.40 **Session 2. New challenges in donation (donor)**
CHAIRS: *Lorenzo Piemonti, Milan, Italy*
Johann Pratschke, Berlin, Germany
- 11.10 **What is the crucial information for accepting an organ? Are scoring systems helpful?**
Raja Kandaswamy, Minneapolis, United States
- 11.40 **Update on marginal donor utilization**
Peter Friend, Oxford, United Kingdom
- 12.10 **Decreasing numbers for beta-cell replacement: what is the reason?**
Antonio Secchi, Milan, Italy

OBJECTIVES | To review recent developments in pancreas and islet transplantation.

TARGET AUDIENCE | Transplant surgeons and physicians, transplant coordinator, nurses and medical student with an interest in transplantation of pancreas and islets.



The European Pancreas and Islet Transplantation Association is a section of ESOT founded to provide a Forum for the pancreas and islet transplantation community in Europe.

GOALS | To facilitate the exchange of information of the field of pancreas and islet transplantation.

AIMS | The aim of EPITA is to contribute to the development of the pancreas and islet transplantation field and of alternate forms of beta-cell replacement therapy for the benefit of patients suffering from type 1 diabetes.

SPECIALTY UPDATE SYMPOSIUM EKITA

09.00 – 12.20

**EKITA & ERA-EDTA DESCARTES
Joint Symposium. Humoral alloimmunity**

09.00 – 10.40

Session 1

CHAIRS: *Fritz Diekmann, Barcelona, Spain*
Ondrej Viklicky, Prague, Czech Republic



09.00

Basics of the HLA system

Caner Süsal, Heidelberg, Germany

09.20

External validity and variability of solid phase results

09.40

HLA single epitope matching becomes real?

Frans Claas, Leiden, The Netherlands

10.00

Preformed HLA DSAs and outcomes

Christophe Legendre, Paris, France

10.20

De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)

Hans J. W. de Fijter, Leiden, The Netherlands

10.40 – 11.00

Break

11.00 – 12.20

Session 2

CHAIRS: *Fritz Diekmann, Barcelona, Spain*

11.00

Alloimmunity trough non-HLA, the human knock out experiment

Rainer Oberbauer, Vienna, Austria

11.20

Complement blockade and outcomes – novel approaches beyond eculizumab

Georg Böhmig, Vienna, Austria

11.40

Treatment of ABMR features in management biopsies

Ondrej Viklicky, Prague, Czech Republic

12.00

Underlying mechanisms of spontaneous operational tolerance

Annick Massart, Brussels, Belgium

OBJECTIVES | To provide an overview and offer specific solutions for the 'complicated' /sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

TARGET AUDIENCE | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.



EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.

GOALS | The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

AIMS | The ultimate aim of EKITA is the optimization of transplantation through activities in research, education, clinical collaboration and health policy.

SPECIALTY UPDATE SYMPOSIUM BSC

09.00 – 12.50

Development, ageing and regeneration

09.00 – 11.00

BSC SessionCHAIR: *Henri Leuvenink, Groningen, The Netherlands*

09.00

Organogenesis and development of organs C18*Stephen A. Duncan, Charleston, United States*

09.45

Ageing donor organs and recipients' immune systems*Michiel Betjes, Rotterdam, The Netherlands*

10.30

Generation of kidney tissue from iPS*Minoru Takasato, Kobe, Japan*

OBJECTIVES | To give in-depth insight in biological processes related to ageing. To provide general insight in organ development and regeneration. To implement general knowledge of ageing and regeneration in the transplantation field.

TARGET AUDIENCE | Basic scientists, transplant immunologists, regenerative medicine researchers, transplant physicians.

11.10 – 12.50

Joint BSC and VCA SessionCHAIRS: *Henri Leuvenink, Groningen, The Netherlands**Gerald Brandacher, Baltimore, United States*

11.10

VCA and regenerative medicine: a perfect couple?*Gerald Brandacher, Baltimore, United States*

11.20

Creating stem cell niches in vitro*Speaker to be confirmed*

11.50

Engineering functional tissues: The Holy Grail or an attainable goal?*Tahera Ansari, Harrow, United Kingdom*

12.20

Pediatric reconstructive transplantation*Lawrence Levin, Philadelphia, United States*

The Basic Science Committee promotes Basic Science in transplantation in Europe.

GOALS | Translation of innovation into clinical activity.
Communication between basic scientists and clinicians.
Collaboration between laboratories in Europe.



SPECIALTY UPDATE SYMPOSIUM VCA



09.00 – 12.50

Beyond hand and face transplantation

09.00 – 11.00

VCA Session

09.00

Uterus transplantation: current status and future directions*Mats Brannstrom, Göteborg, Sweden*

09.30

Penis transplantation: a viable option to restore form and function*Frank Graewe, Stellenbosch, South Africa*

10.00

Regenerative medicine and VCA - competitors or perfect couple?*Liam Grover, Birmingham, United Kingdom*

10.30

Novel technologies for local skin-specific drug delivery*Constantin Coussios, Oxford, United Kingdom*

OBJECTIVES | To discuss the latest developments and new indications in VCA. Discuss new strategies of cell-based immune modulation for VCA. Highlight how cutting edge technologies from tissue engineering and regenerative medicine can help advance the field of VCA.

TARGET AUDIENCE | Surgeons, physicians, researchers, transplant coordinators.

11.10 – 12.50

Joint BSC and VCA Session*CHAIRS: Henri Leuvenink, Groningen, The Netherlands**Gerald Brandacher, Baltimore, United States*

11.10

VCA and regenerative medicine: a perfect couple?*Gerald Brandacher, Baltimore, United States*

11.20

Creating stem cell niches in vitro*Speaker to be confirmed*

11.50

Engineering functional tissues: The Holy Grail or an attainable goal?*Tahera Ansari, Harrow, United Kingdom*

12.20

Pediatric reconstructive transplantation*Lawrence Levin, Philadelphia, United States*

VCA has opened a new chapter in the field of transplantation, reconstructive and restorative surgery. This committee brings together 8 representatives of major European teams at the forefront in this field.

GOALS | Our goal is to raise the scientific and clinical development of Vascularized Composite Allotransplantation (VCA) in Europe and to serve as a platform for scientists and clinicians for information and exchange.

SPECIALTY UPDATE SYMPOSIUM ELPAT

09.00 – 12.50

Hot topics in living and deceased donation

09.00 – 10.30

Session 1

CHAIRS: *Annette Lennerling, Göteborg, Sweden*
Willem Weimar, Rotterdam, The Netherlands

09.00

Children as deceased donors

Marion Siebelink, Groningen, The Netherlands

09.30

How and why should we perform psychological screening of living donors

Emma Massey, Rotterdam, The Netherlands

10.00

Pushing for more anonymous (unspecified) living kidney donations ?

Christopher Burns-Cox, London, United Kingdom

10.30 – 11.00

Break

11.00 – 12.50

Session 2

CHAIRS: *Annette Lennerling, Göteborg, Sweden*
Willem Weimar, Rotterdam, The Netherlands

11.00

Is promotion of altruistic living donation killing altruism of the deceased?

Leonardo de Castro, Singapore, Republic of Singapore

11.30

Questioning the definitions of death

Michael Nair-Collins, Tallahassee, United States

12.00

Opportunities and hurdles in research in deceased donation

Rutger Ploeg, Oxford, United Kingdom

OBJECTIVES | To increase the knowledge, understanding, and skills to implement a successful living kidney exchange program.

TARGET AUDIENCE | Nephrologists, surgeons, psychologists, social workers, transplant coordinators, nurse practitioners.



Ethical, Legal, and Psychosocial Aspects of Organ Transplantation (ELPAT) is a European platform that brings continuity and progress in European research and dialogue on ethical, legal and psychosocial aspects of organ donation and transplantation.

GOALS | Provides a forum for discussion about ethical, legal, and psychosocial problems and questions related to donation and transplantation; Organizes regular, international open and invitational conferences.



SPECIALTY UPDATE SYMPOSIUM ECTTA

09.00 – 12.50

Molecular diagnostics in thoracic transplantation

09.00 – 10.40

Session 1. Joint Session ECTTA-ERS**To provide insights in key features of lung transplantation**CHAIRS: *Arne Neyrinck, Leuven, Belgium*
Robin Vos, Leuven, Belgium

09.00

How to personalise CLAD management*Robin Vos, Leuven, Belgium*

09.20

Can LAS survive in Europe?

09.40

Should we move from ventilation to awake ECMO?

10.00

Is EVLP a tool for immunoregulation?*James Fildes, Manchester, United Kingdom*

10.20

How extended is my donor?*Christian Benden, Zurich, Switzerland*

10.40 – 11.00

Break

11.00 – 12.50

Session 2. Joint Session ECTTA-ESC**Advanced heart failure - when drugs alone are not enough: a case-based approach**CHAIR: *Luciano Potena, Bologna, Italy*

11.00

The patient sliding on inotropes*Andreas Zuckermann, Vienna, Austria*

11.20

Right ventricular failure: LVAD, temporary RVAD or BiVAD?*Arjang Ruhparwar, Heidelberg, Germany*

11.40

When to refer a patient for heart transplant or LVAD: a stepwise approach

12.00

Palliation and end of life care in end-stage heart failure*Jillian Riley, London, United Kingdom*

OBJECTIVES | To provide updates on the etiologies, mechanisms, treatment strategies and diagnostic tools of early and late dysfunction of the transplanted heart and lungs. The lectures will focus on the main strategies and mechanisms leading to graft dysfunction starting from donor and organ management, to prevention of long-term chronic immunological injury leading to graft impairment.

TARGET AUDIENCE | Cardiologists, pneumologists, cardio-thoracic surgeons, anesthesiologists, transplant coordinators.



The Thoracic Committee has been endorsed to promote initiatives aimed at improving the educational and scientific opportunities ESOT can offer to professionals involved in heart and lung transplantation.

GOALS | Our ambition is to become a gathering home to foster scientific growth, exchange programs, collaborative projects and funding opportunities dedicated to European heart and lung transplantation programs.

AIMS | Improve quality of care for patients with end-stage heart or lung disease and for thoracic organ transplant recipients. Advance education and stimulate networking amongst thoracic transplant professionals.

SPECIALTY UPDATE SYMPOSIUM ETAHP

08.30 – 12.50

Healthy ageing after transplantation: sex, drugs and rock'n'roll

CHAIRS: *Fabienne Dobbels, Leuven, Belgium*
Ignacio Revuelta, Barcelona, Spain

08.40 – 10.00

Session 1. Let's talk about sex

08.40

Sexuality after organ transplantation: shuffling between fears and dreams?

Paul Enzlin, Leuven, Belgium

09.10

Transplant drugs and pregnancy - contraception, pregnancy and breastfeeding

Helene Thomas, Bristol, United Kingdom

09.40

Interactive case discussion. So you want to have a baby: now what?

Andrea Devaney, Oxford, United Kingdom

10.00 – 10.50

Session 2. Cognitive functioning

10.00

Cognitive functioning pre- and post-transplant: eternal sunshine of the spotless mind?

Patrick Smith, Durham, United States

10.30

Interactive case discussion on cognitive functioning. 2 cases with long term perspective:

1. Deliberative non adherence due to cognitive deficit in a liver transplant recipient

Anna Forsberg, Lund, Sweden

2. Cognitive deficit after lung transplantation - a long-term perspective on consequences for self-management

Marion Wessels-Bakker, Utrecht, The Netherlands

11.10 – 12.50

Session 3. Frailty

11.10

The good, the bad and the frailty: new organs in rickety vehicles?

Edwin Van Adrichem, Groningen, The Netherlands

11.40

Optimal nutritional intervention in frailty: more than eating steak!

Francis Hollander, Utrecht, The Netherlands

12.10

Interactive case discussion. Frailty: not only a problem for the older patient - 2 cases

Marjo Van Helden, Nijmegen, The Netherlands

OBJECTIVES | The lectures will focus on post transplant lifestyle problems, the role of nurses and allied health professionals in promoting a healthy lifestyle, and non-medical interventions aiming to improve post-transplant self-management.

TARGET AUDIENCE | Nurses, physical therapists, dieticians, social workers, occupational therapists psychologists, among other allied healthcare professionals.



ETAHP reaches out to nurses (e.g. clinical nurses, advanced practice nurses and nurse coordinators (recipient care), psychologists, physical therapists, occupational therapists, social workers, dieticians, pharmacists and other disciplines working in the field of transplantation.

GOALS | Within ETAHP, nurses and allied healthcare professionals throughout Europe will be united to ensure the best care possible to all transplant patients, with the aim to optimize patient outcomes.

AIMS | We will do so by creating a strong European interdisciplinary platform to: share evidence based knowledge; exchange experiences and provide training; facilitate research and clinical collaborations; set the standards for the quality of care in transplant nursing and for allied health professionals.

ORGAN DONATION BY EDTCO



09.00 – 14.30	The next industrial revolution: new role for the transplant coordinator in organ recovery and repair
09.00 – 09.10	Welcome
09.10 – 10.40	Industry 4.0: New role for the transplant coordinator in organ recovery and repair CHAIRS: <i>David Paredes, Barcelona, Spain</i> <i>Dirk Ysebaert, Edege, Belgium</i>
09.10	Heart donation in DCD donors: an option for other countries?
09.30	Ex situ organ perfusion: what are the benefits and the risks for organ repairing?
09.50	New role and responsibilities: transplant technicians in organ preservation (in situ/ex situ)
10.10	Discussion with the experts
10.40 – 10.55	Break
10.55 – 12.30	Donation revolution: changing paradigms CHAIRS: <i>Julien Charpentier, Paris, France</i> <i>Carl-Ludwig Fischer Froehlich, Frankfurt, Germany</i>
10.55	Changes in cerebro-cardiovascular treatment incorporating donation as part of the end of life care
11.15	Increase of patients in therapeutic ECMO, does it interfere in organ donation? <i>Régis Bronchard, Malakoff, France</i>
11.35	Matching expanded donor profiles to selected recipients: HIV to HIV, successfully treated HCV to naive recipients?
11.55	Discussion with the experts
12.30 – 14.30	Lunch symposium. Living donation: the redefined role of transplant coordinator? CHAIRS: <i>Nichon Jansen, Leiden, The Netherlands</i> <i>Sandor Mihaly, Budapest, Hungary</i>
12.30	Pros and cons of transplant coordinators as donor advocate
12.50	It's time for financial incentives to promote living donation?
13.15	New challenges in living donation: Europe confronting with transplant tourism and organ trafficking
13.40	Paired kidney exchange between European countries to improve transplant opportunities
14.05	Discussion with the experts and closing remarks

OBJECTIVES | To promote better understanding of the barriers to deceased donation. To develop knowledge and skills in end of life care, donor management and family support. To enhance collaboration between healthcare professionals working in the fields of intensive care medicine and organ and tissue donation.

TARGET AUDIENCE | Healthcare professionals involved in intensive care and emergency medicine, end of life care, organ and tissue donation and coordination. Patient, family and society representatives, EU commissioners and political representatives.



EDTCO is a section within ESOT dedicated to donation and procurement activities.

GOALS | Increase organ and tissue availability. Ensure the quality and safety of organs and tissues for transplantation. Optimise the safety of living donors and care for deceased donors and their relatives. Optimise potential recipient care and follow-up through effective clinical coordination.

AIMS | To establish clinically effective programmes in organ and tissue donation, procurement and transplantation by supporting and representing all healthcare professionals involved in the process.

WORKSHOP BY YPT

09.00 – 12.00

The transplant team: all for one - one for all

The ESOT YPT Workshop and its Presidential Debate gives you a chance to engage with a variety of speakers in a lively 'town hall' format, as well as connecting with other young transplant professionals from around the world.

The session will begin with talks from three key presenters on the past, present, and future of transplantation and open Q&As with each presenter. The second part sees sets of two speakers take contradicting viewpoints on several of the key issues facing young transplant professionals and tackling questions from the moderator and the audience.

CREATORS: *Francesca Tinti, Roma, Italy*
Mohammed Zeeshan Akhtar, Oxford, United Kingdom

09.00 – 10.35

Part I. The future of transplantation: 3 lectures on past, present and future

CHAIRS: *Alice Koenig, Lyon, France*
Thomas Resch, Innsbruck, Austria

09.05

The future of transplantation - historical perspective

Sir Roy Calne, Cambridge, United Kingdom

09.25

Open Q&A with Roy Calne

09.35

The future of transplantation - present perspective

Jan Lerut, Brussels, Belgium

09.55

Open Q&A with Jan Lerut

10.05

The future of transplantation - future perspective

Igor Sauer, Berlin, Germany

10.25

Open Q&A with Igor Sauer

10.35 – 10.50

Coffee break

10.50 – 12.00

Part II. Presidential debate

'Town Hall' format. Moderated discussion group in which a large audience is invited. The audience is composed of participants and a small number of spokespeople, who will address questions to the 2 speakers. A decided number of questions will come from the audience, while others will be posed by the moderator. The moderator will choose from a list of questions prepared before the event.

**The theme: Career development in Europe - personal experience**

CHAIR: *John Forsythe, Edinburgh, United Kingdom*

10.50

Introduction

10.55

Segment 1. The bittersweet life of a transplant trainee: 'I can't get no ...'

Undine A. Gerlach-Runge, Berlin, Germany
Olivier Aubert, Paris, France

11.15

Segment 2. The importance of pre- and post-transplant care: 'Love your -ologist'

Georgios Vrakas, Oxford, United Kingdom
Laure Elkrief, Geneva, Switzerland

11.35

Segment 3. The importance of research and publication: 'You're only as good as your impact factor'

Carole Guillonnet, Paris, France (TBC)
Simon Knight, Oxford, United Kingdom

11.55

Closing remarks and invitation to the Young Professional Journey at ESOT2017

John Forsythe, Edinburgh, United Kingdom

OBJECTIVES | Provide insights and promote debate on education and career development for young professionals in transplant. The workshop is divided into three parts focussing on different aspects around a common theme on education and career development.

SPECIAL SESSION

11.20 – 14.30

The coolest clinical trials in transplantation sponsored by the EU

Since the beginning of transplantation, clinical trials entertained in Europe contributed to the advancement of this exciting field. Not only large multicenter studies executed by pharmaceutical companies but also investigator-driven research is strongly present in Europe and contributing to the advancement of our field. Under the umbrella of the FP7 and HORIZON2020 frameworks of the European Commission, the EU is sponsoring large international research networks, also in transplantation. In this session, we listen to the stories of the protagonists in the EU-sponsored projects in the field of solid organ transplantation, and discuss the opportunities and hurdles encountered by these large international collaborative networks.

CHAIRS: *Pierre Marquet, Limoges, France*
Maarten Naesens, Leuven, Belgium

11.30

EU-funding of innovative approaches to solid organ transplantation

Jürgen Sautter, European Commission, Brussels, Belgium

11.50

ONE - A unified approach to evaluating cellular immunotherapy in solid organ transplantation

Edward K. Geissler, Regensburg, Germany

12.10

Bio-DrIM - Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation

Petra Reinke, Berlin, Germany

12.30 – 13.10

Lunch break

13.10

EUROSTAM - A Europe-wide strategy to enhance transplantation of highly sensitized patients on basis of acceptable HLA mismatches

Frans Claas, Leiden, The Netherlands

13.30

BIOMARGIN - Biomarkers of renal graft injury

Pierre Marquet, Limoges, France

13.50

COPE - Consortium for organ preservation in Europe: latest news

Rutger Ploeg, Oxford, United Kingdom

Scientific programme



Sunday 24 September



PLENARY SESSION 1

14.45 – 17.30

Big Bang in Transplantation

The creators view

The session will take you on a journey from the origins of transplantation to the present day. Recent advances in science open the gate to extending human life, defying nature. However, we are also learning from nature as to how to extend the life of organs and the entire human body. On the brink of the biggest adventure of the human race, stepping on a different planet, we face questions about the very essence of humanity.

CREATED BY: *Maarten Naesens, Leuven, Belgium*
Gabriel Oniscu, Edinburgh, United Kingdom

CHAIRS: *Josep Maria Grinyó, Barcelona, Spain*
Vassilios Papalois, London, United Kingdom

14.45

Welcome address by the Congress Chairs,
Valentín Cuervas-Mons, Madrid, Spain and Antonio Román, Barcelona, Spain

15.00

ESOT presents: A story never before told!

15.15

A patient experience and viewpoint
Carole Lamarque, Antwerp, Belgium

15.40

Hibernation and preservation
Robert H. Henning, Groningen, The Netherlands

16.00

Near future: a glimpse into the on-going / near future of transplantation
Gerald Brandacher, Baltimore, United States

16.25

KEYNOTE **The human fate from a universal perspective - the race to Mars**
John Bradford, Atlanta, United States

17.45 – 18.45

e-Poster opening

17.45 – 18.45

Elevator Pitch sessions

17.45 – 18.45

Brief oral sessions





Monday 25 September

EDUCATIONAL TRACK SESSION 1

07.30 – 09.00

Histocompatibility: your worst nightmare?

CHAIR: *Frans Claas, Leiden, The Netherlands*
David Taube, London, United Kingdom



07.45

Application of Luminex® assays before and after transplantation

Christophe Legendre, Paris, France

08.00

From actual towards virtual crossmatch

Craig Taylor, Cambridge, United Kingdom

08.15

HLA epitope matching

Sebastiaan Heidt, Leiden, The Netherlands

08.30

Hidden sensitization: the memory B cell repertoire

Oriol Bestard, Barcelona, Spain

EDUCATIONAL TRACK SESSION 2

07.30 – 09.00

Live donation

CHAIRS: *Paolo Muiesan, Birmingham, United Kingdom*
Raj Thuraisingham, London, United Kingdom



07.45

Laparoscopy replacing open surgery in live liver donation

Ki Hun Kim, Seoul, South Korea

08.00

Governance and near miss events in live liver donation

Juan Carlos García-Valdecasas, Barcelona, Spain

08.15

Minor clinical abnormalities in kidney donors

Rachel Hilton, London, United Kingdom

08.30

Teaching minimally-invasive live donor nephrectomy

Lloyd Ratner, New York, United States

08.00 – 09.00

Full oral sessions

08.00 – 09.00

Brief oral sessions



STATE OF THE ART 1

09.10 – 10.40

Organ preservation and enhancements



The creators view

2017: The limitation of available organs and changing demographics are challenges hindering a more rapid growth in organ transplantation. Clinical efforts and a research focus towards making more organs functioning better and increasing the number of organs available for transplantation are ever more important goals. The race is on: will it be organ reconditioning or creating more organs off the shelf? This session will discuss some of the recent developments that may make organ shortage a thing of the past.

CREATED BY: *Gabriel Oniscu, Edinburgh, United Kingdom*
Jacques Pirenne, Leuven, Belgium

CHAIRS: *Constantino Fondevila, Barcelona, Spain*
Jacques Pirenne, Leuven, Belgium

09.10

Organ reconditioning should start in the donor

Gabriel Oniscu, Edinburgh, United Kingdom

09.30

Ex-situ organ reconditioning living up to the promise?

Peter Friend, Oxford, United Kingdom

09.50

Origami based tissue engineering

Nathaniel Hwang, Seoul, South Korea

10.10

Choice cuts: growing organs in alternative environments

Pablo Juan Ross, Davis, United States

STATE OF THE ART 2

09.10 – 10.40

Mix and match: the right organ for the right recipient**The creators view**

Selecting the right organ for the right patient is an increasing challenge in transplantation. To maintain good outcomes is an increasing challenge in light of both donors and recipients presenting with more unfavorable characteristics. In this session we will focus on global aspects of donation and transplantation and subsequently zoom in on 3 categories of recipients that we commonly encounter in our transplantation clinics. Sergio Leone would name them: The Immunized, The Old and The Diabetic.

CREATED BY: *Valentin Cuervas-Mons, Madrid, Spain*
Eelco de Koning, Leiden, The Netherlands

CHAIRS: *Valentin Cuevas-Mons, Madrid, Spain*
Eelco de Koning, Leiden, The Netherlands

09.10

World Overview on Transplantation Activities (a report of the Global Observatory on Donation & Transplantation)

Beatriz Mahillo, Madrid, Spain

09.30

The immunized patient

Frans Claas, Leiden, The Netherlands

09.50

The old patient

Uwe Heeman, Munich, Germany

10.10

The diabetic patient

Raja Kandaswamy, Minneapolis, United States

STATE OF THE ART 3

09.10 – 10.40

The biomarker perspective: prime time or perpetual promise?**The creators view**

Personalised treatment seems the new Holy Grail in medicine. But is it achievable and how far have we advanced in transplantation at this point? In this session, we discuss the experience of large consortia in their search for biomarkers for non-invasive diagnosis of rejection, for guidance on immunosuppression and for patient risk stratification. In addition, we will show that the efforts to discover and validate innovative biomarkers are huge and that the pipeline towards clinical implementation is long. Finally, we look into the mirror but also the crystal ball, evaluating the achievements made to date and the promises for the future.

CREATED BY: *Oriol Bestard, Barcelona, Spain*
Maarten Naesens, Leuven, Belgium

CHAIRS: *Oriol Bestard, Barcelona, Spain*
Alberto Sánchez-Fueyo, London, United Kingdom

09.10

BIOMARGIN - systems biology for non-invasive diagnosis of rejection

Wilfried Gwinner, Hannover, Germany

09.30

BIO-DRIM - marker-assisted immunosuppression individualization

Petra Reinke, Berlin, Germany

09.50

CTOT - biomarkers for transplant risk stratification

Peter Heeger, New York, United States

10.10

The biomarker verdict: prime time or perpetual promise?

Dany Anglicheau, Paris, France

BIG BANG 1



11.10 – 12.40

Technology enhanced medicine

The creators view

We are living in a fast forward moving age, where the convergence of rapidly developing technologies are holding the potential to radically improve and disrupt our day to day life. In this session we invite you to have a glance into the future to see how transplantation will look like years ahead. You will learn a CRISPR way to engineer the human genome, realise that soft robots can support or replace organ function and be impressed by the enormous potential of stem cell biology for generation of human tissues and organs.

CREATED BY: *Pietro Cippà, Zurich, Switzerland*
Olivier Thaumat, Lyon, France

CHAIRS: *Pietro Cippà, Zurich, Switzerland*
Olivier Thaumat, Lyon, France

11.10

A CRISPR way to engineer the human genome

Angelo Lombardo, Milan, Italy

11.40

Cardiovascular devices with a difference – light reflecting balloons and soft robots

Ellen Roche, Cambridge, United States

12.00

KEYNOTE Genetic, epigenetic and cellular approaches to combat disease and aging

Juan Carlos Izpisua Belmonte, La Jolla, United States

11.10 – 12.40

Best abstract challenge

11.10 – 12.40

Full oral sessions



13.00 – 14.00

Future leaders on stage: life-changing stories

Are you passionate about your research or clinical area? Show us on a stunning stage!

The creators view

The *Young Professionals in Transplantation* have launched a competition to future leaders in transplantation to give a seminal presentation at the ESOT congress. Young Professionals have been selected through a call for action on social media. Have a look at the exciting and inspirational presenters that have been selected under 40 years old.

CREATED BY: *Francesca Tinti, Rome, Italy*
Zeeshan Akhtar, Oxford, United Kingdom

CHAIRS: *Francesca Tinti, Rome, Italy*
Mohammed Zeeshan Akhtar, Oxford, United Kingdom

13.00

A very personal story of success and failure: my journey to social media

Omar Taco, Barcelona, Spain

13.20

Life-changing event: 'To improve is to change, to be perfect is to change often.' (Winston Churchill)

Natalie Vallant, Innsbruck, Austria

13.20

Life-changing event: a love worth giving

Luke Yates, London, United Kingdom

13.00 – 14.00

Elevator Pitch sessions

13.00 – 14.00

Brief oral sessions

PLENARY SESSION 2

14.05 – 15.35

Trials and tribulations in transplantation**The creators view**

Some of the established frameworks and conventional approaches in transplantation are outdated and hinder further progress in the field: endpoints such as BPAR may be less relevant in the modern era while surrogate endpoints e.g. for long term KTx survival are lacking. We herein attempt to shake up your minds and engage in a mind-set that challenges some of the things considered to be 'true' or important. Let us rethink the relevance and value of established tools for promotion of progress in clinical science and face the need for change and the challenges that come with it. Welcome to a session that will be rebellious and provocative but also constructive and productive.

CREATED BY: *Mark Dahlke, Regensburg, Germany*
Alexandre Loupy, Paris, France

CHAIRS: *Robert Montgomery, New York, United States*
Gabriel Oniscu, Edinburgh, United Kingdom

14.05

What to do when randomized controlled trials stop working

Alexandre Loupy, Paris, France

14.25

I can induce tolerance but nobody wants to believe me

Alberto Sánchez-Fueyo, London, United Kingdom

14.45

Define success in the 2017 transplant world; a path to happiness

Flavio Vincenti, San Francisco, United States

15.05

KEYNOTE Managing change with big data**BIG BANG 2**

16.00 – 17.00

Value and costs of science and patient care in transplantation: the unwanted truth**The creators view**

The idea of this session is to critically reflect on the value and cost-relationship in transplantation – in reference to science, progress, quality of life, patient behaviour including compliance but also regulatory obligations such as working week regulations. The value of life and costs of suffering as well as the implications of money and patient but also physician behaviour are much debated issues in modern health care. We will touch on strategic thinking in research funding, the implementation from lab inventions to successful enterprises and what can be learned from the free market. In this session, we aim to draw a modern picture of the actual circumstances in healthcare with respect to both the finances of a treatment, but also patient behaviour and their implications on outcome and quality of care. You will experience a different and fresh view on patient care in a rapidly changing environment.

CREATED BY: *Stefan Schneeberger, Innsbruck, Austria*
Dorry Segev, Baltimore, United States

CHAIRS: *Stefan Schneeberger, Innsbruck, Austria*
Dorry Segev, Baltimore, United States

16.00

The price for progress

Wim Bens, Maastricht, The Netherlands

16.20

The changing circumstances in health care and their consequences

Scott Halpern, Philadelphia, United States

16.40

The price for patient satisfaction

Sheila Jowsey, Rochester, United States

16.00 – 17.00

Brief oral sessions

16.00 – 18.00

Full oral sessions



16.00 – 18.00

From learners to leaders and Campfire session

16.00

ESOT Education – ESOT Transplant Live & Live Events

Frank Dor, London, United Kingdom

John Forsythe, Edinburgh, United Kingdom

16.10

KEYNOTE Time is now – modern education

William Plant, Cork, Ireland

16.40

From learners to leaders: introducing the Freudian Walk

O Captain My Captain – how the journey continues

Luca Toti, Rome, Italy

16.50

A growing experience – Part I: keeping the balance

Maruska Nizzi, Milan, Italy

17.00 – 18.00

Transplant Education: the Campfire session

See more information on page 36

17.00

Freudian Walk (3 crews / 3 topics about learning/communicating/sharing)

Crew 1 with captain *Wojciech Polak, Rotterdam, The Netherlands*

Crew 2 with captain *Jacopo Romagnoli, Rome, Italy*

Crew 3 with captain *Luca Toti, Rome, Italy*

17.20

A growing experience – Part II: tips and tricks from senior experts

Maruska Nizzi, Milan, Italy

17.30

Campfire Live (3 crews / 3 campfires)

Crew 1 mentored by captain *Wojciech Polak, Rotterdam, The Netherlands*

Crew 2 mentored by captain *Jacopo Romagnoli, Rome, Italy*

Crew 3 mentored by captain *Luca Toti, Rome, Italy*

17.50

Sharing is caring – a 'post' to the leaders

Maruska Nizzi, Milan, Italy

Luca Toti, Rome, Italy

Face to Face with the Expert



17.00 – 18.00

The Devil's Advocate: a moderated controversy in basic science**The
creators
view**

The format of this session will be the presentation of the article by the author followed by a critical discussion by the 'opponent' and a rebuttal and general discussion with the audience. It will be a highly interactive session.

CREATED BY: *Olivier Thauvat, Lyon, France*
Thomas Wekerle, Vienna, Austria

Case 1. New insights in the priming of recipient's immune system***Donor dendritic cell-derived exosomes promote allograft-targeting immune response***

Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, Sullivan ML, Gibson GA, Watkins SC, Larregina AT, Morelli AE. Journal of Clinical Investigation. Aug 1, 2016; 126(8):2805-20. doi: 10.1172/JCI84577. Epub 2016 Jun 27.

17.00

Defender: *Adrian Morelli, Pittsburgh, United States*

17.20

Opponent: *Gavin Pettigrew, Cambridge, United Kingdom*

17.30

Discussion

Case 2. Impact of microbiota on transplantation outcomes***The composition of the microbiota modulates allograft rejection***

Yuk Man Lei, Luqiu Chen, Ying Wang, Andrew T. Stefka, Luciana L. Molinero, Betty Theriault, Keston Aquino-Michaels, Ayelet S. Sivan, Cathryn R. Nagler, Thomas F. Gajewski, Anita S. Chong, Caroline Bartman and Maria-Luisa Alegre. Journal of Clinical Investigation, June 20, 2016.

17.40

Defender: *Maria Luisa Alegre, Chicago, United States*

17.50

Opponent: *to be confirmed*

18.00

Discussion

17.00 – 18.00

Elevator Pitch sessions

17.00 – 18.00

Brief oral sessions



Tuesday 26 September

EDUCATIONAL TRACK SESSION 3



07.30 – 09.00

Above and below the diaphragm

CHAIR: *Annemarie Weissenbacher, Oxford, United Kingdom*

07.45

Old and new listing criteria for lung and heart transplantation

John Dark, Newcastle, United Kingdom

08.00

Old and new listing criteria for liver, pancreas and intestinal transplantation

Peter Friend, Oxford, United Kingdom

08.15

How do factors from above the diaphragm impact on the outcome of transplantation of organs below the diaphragm?

Stephan Eschertzhuber, Innsbruck, Austria

08.30

Combined transplanted patients - which organ drives the immunosuppressive regimen?

Nassim Kamar, Toulouse, France

EDUCATIONAL TRACK SESSION 4



07.30 – 09.00

Pathophysiology and endpoints on tolerance

CHAIRS: *Cristina Cuturi, Nantes, France**Nina Pilat, Vienna, Austria*

07.45

Clinical tolerance studies

Megan Sykes, New York, United States

08.00

Endpoints and biomarkers for clinical tolerance

Birgit Sawitzki, Berlin, Germany

08.15

Macrophages and the induction of tolerance

Jordi Orchanio, New York, United States

08.30

T-reg induced allograft tolerance in human

Giovanna Lombardi, London, United Kingdom

08.00 – 09.00

Full oral sessions

08.00 – 09.00

Brief oral sessions



STATE OF THE ART 4

09.10 – 10.40

New concepts in transplant infectious diseases: microbiota and beyond**The creators view**

New tools have allowed an unprecedented genetic insight into the composition of our microbiota and our virome. First, we explore the role of the virome and microbiota as it relates to transplantation including potential clinical applications. We aim to elaborate on the impact in transplantation on an individual and epidemiological level. The immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. The new anti-HCV drugs have made eradication of HCV in virtually all patients a realistic goal, but how important is a complete control of viral replication in the context of HCV and other viruses?

CREATED BY: *Maria Luisa Alegre, Chicago, United States*
Marina Berenguer, Valencia, Spain

CHAIR: *Maria Luisa Alegre, Chicago, United States*
Marina Berenguer, Valencia, Spain

09.10

Transkingdom interplay - the complex interactive world of the microbiome
Dave Wang, St. Louis, United States

09.30

Knowledge and clinical applications of microbiota in transplantation
Frederick Bushman, Philadelphia, United States

09.50

Viruses and the recipient immune response: relevant crosstalk in transplantation
Oriol Manuel, Lausanne, Switzerland

10.10

The impact of HCV treatment on liver transplantation
Michael R. Charlton, Salt Lake City, United States

STATE OF THE ART 5

09.10 – 10.40

Cell therapy in clinical trials**The creators view**

Cell therapy may be a suitable adjunct to conventional immunosuppression. Despite a major enthusiasm, however, major issues emerged in the first clinical applications. The question now is: how can technical and regulatory hurdles be overcome within a reasonable time frame? Will cell therapy ever be commercially interesting and will its implementation enhance solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy tomorrow and in 10 years.

CREATED BY: *Pietro Cippà, Zurich, Switzerland*
Marc Dahlke, Regensburg, Germany

CHAIRS: *Marc Dahlke, Regensburg, Germany*
Thomas Wekerle, Vienna, Austria

09.10

Technical and regulatory issues. From the idea to the clinical application
Marlies Reinders, Leiden, The Netherlands

09.30

Sharing clinical experience. What can we learn from hematologists?
Francesco Dazzi, London, United Kingdom

09.50

Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
Suzanne T. Ilstad, Louisville, United States

10.10

The future: clinical applications of stem cells in the context of transplantation vs. regeneration?
Martin Johannes Hoogduijn, Rotterdam, The Netherlands

STATE OF THE ART 6

09.10 – 10.40

One for all or all for one: moving away from protocolized medicine



The creators view

The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall outcome in transplantation. It is increasingly recognized though, that the 'one size fits all' approach does not always optimally reflect the patient's individual need. Hence, the concept of personalized medicine is on everyone's lips. This session aims to confront the reality by focusing on four important topics in the field.

CREATED BY: *Georg Böhmig, Vienna, Austria*
Nicolas Müller, Zurich, Switzerland

CHAIRS: *Georg Böhmig, Vienna, Austria*
Nicolas Müller, Zurich, Switzerland

09.10

Is transplantation ready for systems medicine?

Rainer Oberbauer, Vienna, Austria

09.30

Individualized antimicrobial prophylaxis

Jay Alan Fishman, Boston, United States

09.50

Phenotypic diversity of rejection and allograft dysfunction

Phil Halloran, Edmonton, Canada

10.10

Tailored immunosuppression

Christian Hugo, Dresden, Germany

BIG BANG 3

11.10 – 12.40

Innovation in immunomedication: the modern Prometheus



The creators view

Following the steps of Dr Frankenstein, scientists have begun stitching together disparate biological pieces to create new therapeutic opportunities and, far from sci-fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionise solid organ transplantation will be scrutinised during this Big Bang session.

CREATED BY: *Josep Maria Grinyó, Barcelona, Spain*
Olivier Thaumat, Lyon, France

CHAIR: *Julien Zuber, Paris, France*

11.10

Deciphering and targeting protein-protein interactions: a new challenge in biomedicine

Juan Fernández Recio, Barcelona, Spain

11.30

The potential of bispecific antibodies

Speaker to be confirmed

11.50

Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor

Megan Levings, Vancouver, Canada

12.10

Systems biology applications for prognostication and therapeutics

Patrick Aloy, Barcelona, Spain

11.10 – 12.40

Asia leading the way

(Joint session with the Asian Society for Transplantation)

This session was jointly organized with the Asian Society for Transplantation and aims to highlight some of the significant advancements in transplantation achieved in the recent past. We are proud to bring to your attention programmes and topics from our partners in Asia.

CHAIRS: *Jan Lerut, Brussels, Belgium**Dennis Serrano, Quezon City, Philippines*

11.20

Tissue repair and its relevance to transplantation*Romina Danguilan, Manila, Philippines*

11.40

Challenges in increasing organ donation in Asia*Romina Danguilan, Manila, Philippines*

12.00

ABO incompatible kidney transplantation: future directions*Shiro Takahara, Osaka, Japan*


12.20

State of the art of living donor liver transplantation*Chao Long Chen, Kaohsiung City, Taiwan*

11.10 – 12.40

Elevator Pitch sessions

11.10 – 12.40

Full oral sessions

13.00 – 14.00

Surrogate Endpoints International Workshop**The creators view**

Drug development in transplantation has diminished due to the lack of fitting endpoints, the long timespan between transplantation and graft failure and the low rates of early rejection. At the same time, we find patients suffering from long-term graft loss. Hence it is paramount to establish new principles to allow development of novel therapeutics to treat and prevent this from happening. One of the main objectives in our drive to address this is to identify and validate surrogate markers for long-term graft outcome and identify novel endpoints for trials and drug development. The field of transplantation is facing one of the greatest challenges hindering further advancement of this field and all individuals and institutions involved in this field need to work together to prevail. In this interactive session, we will discuss the need for new endpoints in the field of transplantation, the potential and problems with histology, the applicability of donor-specific antibodies, and the promise of combined calculated markers as surrogate endpoints. We will discuss the progress that has and can be achieved by transplant societies and health authorities. The session will focus on kidney transplantation, although the methodology and conclusions are likely valid also for other organs.

CREATED BY: *Maarten Naesens, Leuven, Belgium*
Stefan Schneeberger, Innsbruck, Austria

CHAIRS: *Maarten Naesens, Leuven, Belgium*
Stefan Schneeberger, Innsbruck, Austria

13.00

Why do we need new endpoints

Mark Stegall, Rochester, United States

13.10

The potential of combined calculated surrogate endpoints

Alexandre Loupy, Paris, France

13.22

The difficult but important place of histology as endpoint

Maarten Naesens, Leuven, Belgium

13.34

DSAs as surrogate endpoint for drug development

Peter Nickerson, Winnipeg, Canada

13.46

Panel discussion

13.00 – 14.00

Brief oral sessions**PLENARY SESSION 3**

14.05 – 15.35

Innovation under pressure: transplant patient care in 2020**The creators view**

Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challenging than ever. While novel technologies may help to effectively monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.

CREATED BY: *Marina Berenguer, Valencia, Spain*
Antonio Roman, Barcelona, Spain

CHAIRS: *John Forsythe, Edinburgh, United Kingdom*
Christophe Legendre, Paris, France

14.05

Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others

Wei-Ping Andrew Lee, Baltimore, United States

14.25

Beyond survival: quality of life after transplantation

Lianne Singer, Toronto, Canada

14.45

New tech for new patients: digital communication and self-monitoring

Giral Magali, Nantes, France

15.05

KEYNOTE New models for patient care: wish for what you care for

Marcel Levi, London, United Kingdom

BIG BANG 4

16.00 – 17.00

Ageing and immortality**The
creators
view**

In this session, we discuss the changing demographics of donors and recipients and its impact on transplantation in reference to organ quality, ischemia-reperfusion injury and immunosenescence. In addition, the biology of ageing and the concept of accelerated ageing after transplantation with its implications on the fate of the graft and the patient are being addressed. As a consequence of the changing demographics, transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. Finally, we will evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.

CREATED BY: *Maarten Naesens, Leuven, Belgium*
Olivier Thauvat, Lyon, France

CHAIR: *Maarten Naesens, Leuven, Belgium*

16.00

Older graft, older recipients, young ideas

Stefan Tullius, Boston, United States

16.20

Accelerated ageing after transplantation

Peter Stenvinkel, Stockholm, Sweden

16.40

Halting aging: the science of rejuvenation

Brian Kennedy, Novato, United States

16.00 – 17.00

The Devil's Advocate: contradictory discussion of clinical science**The
creators
view**

The format of this session will be the presentation of the article by the author followed by a critical discussion by the 'opponent' and a rebuttal and general discussion with the audience. It will be a highly interactive session.

CREATED BY: *Josep Maria Grinyó, Barcelona, Spain*
Rainer Oberbauer, Vienna, Austria

CHAIRS: *Josep Maria Grinyó, Barcelona, Spain*
Rainer Oberbauer, Vienna, Austria

Case 1. Ethical debate**Allocating organs to cognitively impaired patients**

Scott D. Halpern, M.D., Ph.D., and David Goldberg, M.D., M.S.C.E. N Engl J Med 2017; 376:299-301 January 26, 2017 DOI: 10.1056/NEJMp1613858

16.00

Defender: *Scott Halpern, United States*

16.20

Opponent: *Michael Bos, Leiden, The Netherlands*

16.30

Discussion

Case 2. Title pending**Clinical value of C1q assay in antibody-mediated rejection****Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival**

Wiebe, Gareau, Pochinco, Gibson, Ho, Birk, Blydt-Hansen, Karpinski, Goldberg, Storsley, Rush, Nickerson. Am J Transplant. 2017 Mar;17(3):703-711. doi: 10.1111/ajt.14015. Epub 2016 Oct 3.

16.40

Defender: *Peter Nickerson, Winnipeg, Canada*

16.50

Opponent: *Denis Glotz, Paris, France*

16.30

Discussion

16.00 – 17.00 **Brief oral sessions**

17.05 – 18.35 **Full oral sessions**

17.05 – 18.35 **ESOT General Assembly**



18.40 – 19.35 **Elevator Pitch sessions**

18.40 – 19.35 **Brief oral sessions**

19.35 – 20.20 **Rising Stars Networking Cocktail**





Wednesday 27 September

EDUCATIONAL TRACK SESSION 5



07.30 – 09.00

Infection diseases

CHAIRS: *Alain Le Moine, Brussels, Belgium*
Frederike Bemelman, Amsterdam, The Netherlands

07.45

Prophylaxis of infections in solid organ transplantation (including donor derived infections)

Jay Alan Fishman, Boston, United States

08.00

Infectious diseases in the central nervous system of solid organ transplant patients

Peter Portegies, Amsterdam, The Netherlands

08.15

Fungal and yeast infections in SOT patients

José María Aguado, Madrid, Spain

08.30

Impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation

Oriol Manuel, Lausanne, Switzerland

EDUCATIONAL TRACK SESSION 6



07.30 – 09.00

The allograft phenotype and its clinical implications

CHAIRS: *Lorna Marson, Edinburgh, United Kingdom*
Marlies Reinders, Leiden, The Netherlands

07.45

Allo-immune responses: what a clinician should know

Frans Claas, Leiden, The Netherlands

08.00

Rejection phenotypes across organs: revisiting the basics

Chris Bellamy, Edinburgh, United Kingdom

08.15

How to integrate complex histological phenotypes in routine clinical decision making?

Daniel Serón, Barcelona, Spain

08.30

Time to make computer-assisted instead of eminence-based decisions?

Alexandre Loupy, Paris, France

08.00 – 09.00

Full oral sessions



08.00 – 09.00

Brief oral sessions

STATE OF THE ART 7

09.10 – 10.40

Donor management – can we further extend the potential donor pool?**The creators view**

The prerequisite for successful transplantation is the availability of organs. At the same time, selecting suitable organs for transplantation is critical in order to guarantee optimal short- and long-term outcomes. During the last years, we have experienced an increasing interest in strategies to optimize donor management, especially since liberalization of donor criteria has been introduced within the field. In this session, we want to address the idea of further extending the potential donor pool. The focus will be recent innovative approaches and potential risk factors, that might limit further expansion. In this session we want to engage all professionals involved in this topic, including anaesthesiologists, intensivists, nurses, coordinators and transplant physicians in a lively exchange and discussion.

CREATED BY: *Arne Neyrinck, Leuven, Belgium*
Jacques Pirenne, Leuven, Belgium

CHAIR: *Arne Neyrinck, Leuven, Belgium*
Beatriz Domínguez-Gil, Madrid, Spain

09.10

How controlled is my DCD?

Sophie Van Cromphaut, Leuven, Belgium

09.30

Should I perfuse my donor?

Simon Messer, Cambridge, United Kingdom

09.50

Tribulation in designing donor intervention studies

Claus Niemann, San Francisco, United States

10.10

How clean is my donor?

Margaret Hannan, Dublin, Ireland

STATE OF THE ART 8

09.10 – 10.40

Pushing the boundaries in living donation**The creators view**

Live donation has become routine practice in many countries. The expansion of the acceptance criteria for live kidney donors is now challenged by emerging evidence for an increased relative risk for the development of renal failure on the long run. In this context, it is even more important how transplant professionals provide an individual risk assessments for potential donors. But how can we ensure that donors understand the potential risks? Do we have a good screening tool to assess potential psychological risks for live donors? Can we step away from standardized surgical approaches for live donor nephrectomy and adopt a tailor made approach? Should living donor liver transplantation be advocated to replace deceased donor liver Tx? This session focuses on the balance between pushing the limits in the context of potential short and long-term complications in this field.

CREATED BY: *Frank Dor, London, United Kingdom*
Gabriel Oniscu, Edinburgh, United Kingdom

CHAIR: *Bariş Akin, Ankara, Turkey*
Lisa Burnapp, Watford, United Kingdom

09.10

To be or not to be a donor – how can we make sure potential donors understand the risks?

Aisling Courtney, Belfast, Ireland

09.30

Psychosocial evaluation of live donors - the need for a tool to determine the psychological risk

Fabienne Dobbels, Leuven, Belgium

09.50

Tailor made live donor nephrectomy: a conversation between two surgeons

Frank Dor, London, United Kingdom and Gabriel Oniscu, Edinburgh, United Kingdom

10.10

Should live liver donor transplantation be advocated to substitute deceased donor liver Tx?

Yaman Tokat, Istanbul, Turkey

STATE OF THE ART 9

09.10 – 10.40

Cellular interaction in rejection**The creators view**

Transplant rejection involves a coordinated attack of the graft by the recipient's innate and the adaptive immune systems. Although direct visualization of this complex cellular interplay as made possible by recent technological progresses has greatly improved our understanding of rejection pathophysiology, it has also led to unexpected observations. Indeed, like in other chronic inflammatory conditions, organized lymphoid tissue develop in allografts. This session will provide an update on cellular interactions in rejection and will discuss whether intragraft tertiary lymphoid organs contribute to graft rejection and/or tolerance.

CREATED BY: *Lorna Marson, Edinburgh, United Kingdom*
Olivier Thauinat, Lyon, France

CHAIRS: *Carla Baan, Rotterdam, The Netherlands*
Lorna Marson, Edinburgh, United Kingdom

09.10

Visualizing cell trafficking and the underlying allosensitization by two-photon microscopy

Adrian Morelli, Pittsburgh, United States

09.30

T cell migration to vascularized transplants

Fadi Lakkis, Pittsburgh, United States

09.50

Lymphoid neogenesis: a tribute to the travelers

Nancy Ruddle, New Haven, United States

10.10

Intragraft tertiary lymphoid organs: friends and foes

Olivier Thauinat, Lyon, France

PLENARY SESSION 4

11.00 – 12.40

Leadership in transplantation and Presidential Session**The creators view**

Leadership is a key element in our professional lives, yet the attention to professionalism in this area has not received much attention. Much of the potential in our field could be mobilized by enhancing the understanding of the principles in modern leadership. In this final plenary session, you will hear from individuals within and outside of transplantation about their experience and their own views on leadership.

As per the tradition of the ESOT conference, you will also be presented with a summary of the most exciting innovations that have been discussed during the congress in this session.

CREATED BY: *Lorna Marson, Edinburgh, United Kingdom*
Stefan Schneeberger, Innsbruck, Austria

CHAIRS: *Thierry Berney, Geneva, Switzerland ESOT CURRENT PRESIDENT*
Stefan Schneeberger, Innsbruck, Austria ESOT PRESIDENT ELECT

11.00

Clinical: What's hot!

Dennis Hesselink, Rotterdam, The Netherlands

11.20

Basic Science: What's hot!

Oriol Bestard, Barcelona, Spain

11.40

Leadership in transplantation!

Dorry Segev, Baltimore, United States and Robert Montgomery, New York, United States

12.10

KEYNOTE Leadership

Javier Solana, Madrid, Spain

12.30

Presidential address

Stefan Schneeberger, Innsbruck, Austria



Monday 25 Sept
17.00 – 18.00

"O Captain, My Captain" - A Growing Experience



AUDIENCE

Learn
Experience
Communication
Share

Learners
Mentors
Influencers
TransplantPro

The session is designed by the Education Committee and organised by Luca Toti, Wojciech Polak and Jacopo Romagnoli.

Open air Freudian walk and campfire session

MAIN STORYTELLER: *Maruska Caterina Nizzi, Milan, Italy*

STORYTELLERS: *Luca Toti, Wojciech Polak and Jacopo Romagnoli*



The Education Committee is dedicated to:



Submit an abstract

If you are a professional working in transplantation, the scientific committee invites you to submit your work for review at ESOT 2017 Congress.



Contribute to success

Submitting your work and research actively contributes to the success of the meeting. The organizers encourage clinicians and scientists, along the line with the congress theme, to share their latest data with their peers. There will be a separate submission process for clinical management abstracts, in which a clinical case may be identified. Successful review would give you the chance to present your clinical problem to a panel of experts.

Network

Plans are already in place to provide an interactive F2F international meeting, with significant importance to networking aspect, one of the main the reasons to attend. Presentation of submitted works represents the platform for the exchange of information and to communicate in person with other transplant professionals.

Notification of acceptance

(for abstracts submitted before 12 March)

Acceptance of abstracts will be notified on/from **31 May 2017**, when presenters will be advised the allocated category of oral, rapid oral or poster presentation for their paper at this time. Detailed information on presentations will be sent to the presenting author at that time. The presenting author must duly register for the Congress by **13 June 2017**. A reduced, early Registration Fee will apply prior to this deadline. Registering after **13 June 2017**, can affect the inclusion of the abstract in the Final Programme and in the Book of Abstracts.

Late breaking abstract submission

On-line late breaking abstract system will open on **2 June 2017** and your abstract must be submitted on or before **30 June 2017**. Guidelines for abstract preparation and submission are fully described in the Congress website at <http://esot2017.esot.org> where you will be guided through the on-line submission process. Notifications for late breaking will be dispatched on/from **10 July 2017**.

Engage

The format of this meeting offers many possibilities for your abstract to be presented as an 'oral' contribution. An innovative learning environment has been planned, with the aim to give the right visibility and to reward the author's contribution. Abstracts will be selected for either oral, rapid oral or poster presentation, taking account of the author's preference.

Presentations will be allotted as:

Full oral main topic areas presented in large auditorium, to acknowledge the high level of your contribution.

Brief oral revised version of the traditional poster discussion, to offer more prominence to the presentations.

Posters electronically available on tablets and discussed during peer-to-peer 'appointment sessions' for greater visibility.

Elevator pitch new at ESOT Congress. Oral presentations with a spin. These abstract presentations will be held during prescheduled sessions. You will be allowed 1 slide for 'the pitch' to convince 2 judges in 1 minute. If the judges are convinced they'll allow you to present a further 4 more slides, in 5 minutes total presentation time.



What is an Elevator Pitch?

Abstract submissions to Elevator Pitch: a new and rewarding challenge

1 slide • 2 judges • 1 minute

Elevator Pitch abstract presentations will be held during prescheduled sessions. You will be allowed 1 slide for 'the pitch' to convince 2 judges in 1 minute.

What is an Elevator Pitch?

It's a brief speech that outlines an idea for a product, service or project. It is often used by project managers, salespeople and jobseekers as a way to market themselves or their ideas.

An elevator pitch should include why your abstract subject is worthwhile by explaining such things as the outcomes, features and benefits.

If you convince the judges they will let you talk about your abstract in 4 more slides, 5 minutes total presentation. With this highly entertaining presentation, you will gain great visibility.




Increase your visibility and join #elevatorpitch for ESOT 2017!

ARE YOU
**Elevator
Ready?**





ESOT 2017 Congress registration fees



60€ discount
from the relevant
congress fee for
participants with
their own device!

ESOT 2017 will be a paperless congress.

Printed matter will be fully replaced by a multi-feature app to maximise participants' engagement and connectivity.

TYPE OF REGISTRATION	EARLY	REGULAR	LATE
	until 13 June	until 31 August	from 1 September
ESOT Member	600€	700€	730€
Non-member	850€	950€	980€
Easy ESOT: incl. registration to the Congress and ESOT membership fee	700€	800€	830€
Individuals qualifying for a reduced fee, members only *	360€	410€	440€

Fees are inclusive of VAT at the prevailing rate (21% in March 2017)

Reduced fee* (applies only to ESOT members)

Trainees, nurses, transplant co-ordinators, allied health professional / participants from low/middle income countries¹, local hospital staff members.

¹According to World Bank list: <http://data.worldbank.org/country>

Delegate registration fee includes:

- Admission to all scientific sessions
- Access to the exhibition
- Participant's kit with congress material
- Provision of the required device for use throughout the duration of the congress
- Admission to all Specialty Update Symposia
- Access to the delegate lounges
- Admission to poster opening and networking reception
- Refreshment breaks





ESOT Awards 2017

BAC – Best Abstract Challenge

Supported by  **Biotest**

Each award amounts to 2.500 Euro.

The challenge made up of 10 finalists, will take place during the BAC session on Monday 25 September from 11.10 to 12.40.

A selection of 10 outstanding contributions will be made by the ESOT2017 Scientific Program Committee from all submitted abstracts and based on the overall referees' score, the audience will then vote to select 6 winners.

The award winners will be celebrated during the presentation session.



YIA – Young Investigator Awards

Supported by  **Roche**

Each award amounts to 1.500 Euro.

10 awards will be given to young clinicians or scientists (under 40 years of age in 2017), who have submitted abstracts to #ESOT2017 #BigBangBarcelona.

Submitters are requested to select the 'Young Investigator's Award' option in the abstract application process.

The awards are selected by the Scientific Programme Committee of the ESOT2017 Congress, and advised by email at the same time as the abstract notification. The award winners will be celebrated during the presentation session.



StrongerTogether Award

Supported by European National Transplant Societies
The award amounts to 2.500 Euro.*

The award will be given to the largest group of abstracts (minimum 5) submitted by a single transplant centre/unit/institution/hospital.*

The award is selected by the Scientific Programme Committee of the ESOT2017 Congress and advised by email at the same time as the abstract notification.

The award winner will be celebrated on Tuesday 26 September from 19.30 to 20.15 in the Rising Stars Lounge.

* The award will be given to a single centre/unit/institution/hospital – not to individuals.



StrongerTogetherPro Award

The award amounts to 5.000 Euro.*

This award will be given to the group of abstracts (minimum 5) submitted by a single transplant centre/unit/institution/hospital* with the best average score amongst all group of abstracts submitted by single centres/units/institutions/hospitals.

The award is selected by the Scientific Programme Committee of the ESOT2017 Congress and advised by email at the same time of the abstract notification.

The award winner will be celebrated on Tuesday 26 September from 19.30 to 20.15 in the Rising Stars Lounge.

*The award will be given to a single centre/unit/institution/hospital – not to individuals.





ESOT Awards 2017

BE – Best #ESOTtrustedPartner Award

Supported by  **TRANSPLANT**

The award amounts to 500 Euro.

The **#ESOTtrustedPartner** awards will be given to the most active #ESOTtrustedPartner in the time period from 31/01/2017 until the opening event of the congress. A special tool will keep track of social media posts (via Twitter/LinkedIn/Instagram/Facebook).

The award winner will be celebrated on Tuesday 26 September during the coffee break at 15:35 in the ESOT Village.

* Winners will be notified by 24/09/2017

#ESOTtrustedPartner members have a dedicated group on LinkedIn.

The Group: ESOT members are invited to become Trusted Partners to boost communication and information about all activities #PoweredByESOT, with a special focus on the International Transplant Congress which is held every two years.

The Goal: To build on the communication around #ESOT2017 and other educational opportunities #PoweredByESOT, by acting/reacting in this group, echoing in your preferred platforms and sharing the promotional messages prepared for our events.

The official hashtags (# mainly for Twitter, Facebook and Instagram) are:

#ESOT2017 and/or #BigBangBarcelona (Congress)

#PoweredByESOT (any ESOT educational opportunities).



EuroLiver Award

Supported by **EuroLiver**  Foundation

Each award amounts to 1.000 Euro.

The EuroLiver Foundation was set up in 1992 by the late Mr Herman Tob and Prof. Jean-Bernard Otte of the University Hospital St-Luc in Brussels, Belgium in order to support research projects in the field of liver transplantation and organ donation, and also to improve the psychosocial support of both future liver recipients and liver transplant patients.

More info on the past editions available here:

euroLiver.org/content/euroLiver-foundation-awards

2 awards are assigned to young researchers who have made a valuable contribution in relation to these topics.

Awards are assigned by the Scientific Programme Committee and announced before the congress.

The award winners will be celebrated during the presentation Session.



ESOT has always been committed to education and research. At ESOT 2017 Conference we will be pleased to recognize the excellence of professionals who show outstanding results.

YIA and TrustedPartners awardees will be required to be ESOT members for 2017.




ESOT Corporate Partners



GOLD CIRCLE



EDUCATION CIRCLE



SILVER CIRCLE




ESOT 2017 Congress Supporters

PLATINUM



GOLD





ESOT 2017 Congress Supporters


SILVER



BRONZE



EXHIBITORS



NON-PROFIT ORGANISATIONS



Special thanks to our partners and supporters!

As a sponsor or exhibitor ESOT 2017 offers you a strong platform to:

- Meet your target group with the potential to gain 4000 strong business leads.
- Be recognized as the ultimate solution provider.
- To be seen as a principal supporter.
- Have the fundamental face-to-face conversation.
- Promote new products.
- Be associated with the latest medical research in the field of organ transplantation.



ESOT2017 Corporate Symposia

Sunday 24 September

13.00 – 14.30 **Corporate Plenary Symposium**

13.00 – 14.30 **Corporate Parallel Workshops**



Monday 25 September

13.00 – 14.00 **Corporate Parallel Lunch Symposia**



18.00 – 19.30 **Corporate Plenary Symposium**



Tuesday 26 September

13.00 – 14.00 **Corporate Parallel Lunch Symposia**



13.00 – 14.00 **Corporate Parallel Lunch Workshop**

17.00 – 18.30 **Corporate Parallel Symposia**






Ecosystem

ESOT is committed to maximising participant engagement and connectivity, as well as event sustainability. Once again, the ESOT Congress will be fully paperless. At ESOT2017, a dedicated app with its fully digitalized environment will

make your meeting experience easier and more enjoyable than ever, facilitating the interaction with your peers and helping you find the content that is most relevant to you.



About the venue



The CCIB is a unique space that came into being with the 2004 Universal Forum of Cultures, with the goal of welcoming congresses, conventions, exhibitions and official events on the highest level from around the globe.

Its innovative features, unmistakable architecture, cutting-edge technology and sustainable event management, combined with its superb location facing the Mediterranean, make the CCIB an outstanding venue.

CCIB Centre de Convencions Internacional de Barcelona
Pl. de Willy Brandt 11-14, 08019 Barcelona, Spain
www.ccib.es



Hotel accommodation

Barceló Congressos has been appointed as the Official Housing Bureau of ESOT 2017 Congress and is offering you the opportunity to book accommodation in a selection of Barcelona's best hotels at preferential negotiated rates for the attendees. A wide range of

hotel categories will be available in the CCIB area, venue of the congress, some walking distance and others well connected by public transport. Hotel reservations will be made available at a later stage at: www.esot.org

Important dates:

Abstract submission closes 12 March 2017

Notifications dispatched on/from 31 May 2017

Early registration deadline 13 June 2017

Late breaking abstract submission opens 2 June 2017

Late breaking abstract submission closes 30 June 2017

Late breaking abstract submission notifications despatched on/from 10 July 2017



neovii

A future powered by experience

neovii is proud to be a supporter of
the ESOT 2017 Barcelona Congress

Come and visit our booth on
level P0 in the congress centre

Neovii is committed to developing novel therapies
in transplant and haematology/oncology

Come and experience it!



24 - 27 September 2017 · Barcelona · Spain

CONTACTS

ESOT 2017 Congress Secretariat

ESOT OFFICE

Riviera dei Mugnai 8/24

35137 Padua · Italy

Tel: +39 049 859 76 52

Fax: +39 049 210 63 06

esot2017@esot.org



Congress Administrative Secretariat

BARCELÓ CONGRESOS

Pl. Europa 17-19, 1st floor

08908 L'Hospitalet de Llobregat

Barcelona · Spain

Tel: +34 938 823 878

Fax: +34 971 593 811

esot2017@barcelocongresos.com

Transplantation BigBangBarcelona



visit esot.org